Rallybio Corporation (RLYB)
Market Closed
27 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
16. 31
0
0%
$
88.2M Market Cap
- P/E Ratio
- Div Yield
15,644 Volume
-1.55 Eps
$ 16.31
Previous Close 
Want to track RLYB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Seekingalpha | 1 month ago
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Rallybio Corporation (RLYB) M&A Call Prepared Remarks Transcript
Seekingalpha | 4 months ago
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
Zacks | 1 year ago
Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
Rallybio (RLYB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks | 1 year ago
